Arthritis: History and Discovery

The word arthritis simply means “inflammation of a joint” — from the Ancient Greek arthron (joint) and the suffix -itis (inflammation). It is one of the oldest recognized human afflictions: arthritic changes are visible in the skeletons of dinosaurs, Neanderthals, Egyptian mummies, and Bronze-Age bog bodies, and joint disease is described in the very earliest medical writings. But “arthritis” is not one disease. It is an umbrella term covering more than a hundred distinct conditions, and untangling that umbrella — separating degenerative osteoarthritis from autoimmune rheumatoid arthritis from crystal-driven gout — took medicine more than two thousand years and was not finished until the nineteenth and twentieth centuries. This page traces that long sorting-out, with care to mark where the historical record is firm and where it is contested.

Table of Contents

  1. The Word and the Umbrella
  2. Arthritis in Ancient Bones
  3. Hippocrates, Galen, and the Humoral Age
  4. When “Rheumatism” Was One Disease
  5. Rheumatoid Arthritis: First Described (Landré-Beauvais, 1800)
  6. Rheumatoid Arthritis: Named (Garrod, 1859)
  7. Osteoarthritis Splits Off
  8. The Rheumatoid Factor and Cortisone
  9. Willow Bark to Aspirin: An Ancient Remedy
  10. Research Papers and References
  11. Connections

The Word and the Umbrella

“Arthritis” is built from two Greek pieces: arthron, meaning a joint or articulation, and -itis, a suffix that the medical tradition came to attach to inflammation. Literally, then, the term promises nothing more specific than “a joint that is inflamed.” English dictionaries record the word entering the language in the sixteenth century (the Online Etymology Dictionary and Merriam-Webster cite a first attested use around 1543), but the Greek root is far older and runs straight back to classical medicine.

That breadth is the single most important fact in the history of arthritis, and the source of endless confusion. Because any swollen, painful, or stiff joint “is” arthritis, the label has always covered a crowd of utterly different diseases: the slow cartilage wear of osteoarthritis; the immune system attacking the joint lining in rheumatoid arthritis; needle-sharp uric-acid crystals in gout; the spine-fusing inflammation of ankylosing spondylitis; the joint damage of psoriatic arthritis and lupus; and infections, injuries, and childhood forms besides. Modern rheumatology recognizes well over one hundred named types. The history that follows is therefore less a story of discovering “arthritis” — people always knew joints hurt — and more the story of slowly, painstakingly pulling the umbrella apart into the distinct illnesses we now treat differently.

Back to Table of Contents

Arthritis in Ancient Bones

Joint disease is older than humanity itself. The study of disease in ancient remains — paleopathology — finds degenerative arthritic change in the fossil skeletons of dinosaurs and in countless later vertebrates, and osteoarthritis has been a constant companion of humans and our hominin relatives since Paleolithic times. Arthritic joints have been documented in Neanderthal skeletons and, abundantly, in the skeletons and mummies of ancient Egypt, where standardized whole-body CT studies of mummies have catalogued osteoarthritis alongside other diseases. Because worn cartilage leaves telltale changes in the underlying bone — polished “eburnated” joint surfaces, marginal spurs (osteophytes), and altered joint shape — degenerative arthritis is one of the most reliably readable conditions in archaeological skeletons.

Inflammatory and crystal arthritis can sometimes be read in old bones too: erosive changes consistent with rheumatoid-type disease, the fused spines of ankylosing spondylitis, and the punched-out bone erosions of long-standing gout have all been proposed in skeletal collections, though such retrospective diagnoses are necessarily more cautious than the unmistakable wear of osteoarthritis. A long-running scholarly debate even asks whether true rheumatoid arthritis existed in the Old World before modern times or whether it may have been comparatively rare or unrecognized until the period around 1800 — a question we return to below, and one that is genuinely unresolved rather than settled.

The lesson of the bones is simple and humbling: arthritis is not a disease of the modern, sedentary, processed-food world. People — and animals — have lived with worn and inflamed joints for as long as there have been joints to wear, and the search for relief is correspondingly ancient.

Back to Table of Contents

Hippocrates, Galen, and the Humoral Age

The earliest written medicine already grappled with joint disease, though without our categories. In ancient Greece, the Hippocratic writers (fifth to fourth century BCE) described painful joint conditions and used a vocabulary organized by the body part affected: podagra for pain seizing the foot or great toe, chiragra for the hand, and gonagra for the knee. Hippocrates associated podagra — what later medicine would identify as gout — with a rich man’s lifestyle and observed that it tended to spare younger women and pre-pubertal men, clinical observations that remain broadly recognizable today. He explained these and other ailments through the humoral theory: disease arose when the four bodily humours (blood, phlegm, yellow bile, black bile) fell out of balance, and a humour settling or “flowing” into a joint produced its swelling and pain.

That idea of a humour flowing gave us another enduring word. The Greek rheuma meant a flux or stream, and the notion that a morbid fluid flowed down into the joints produced “rheumatism” — the umbrella ancestor of the modern specialty name rheumatology. The great second-century physician Galen systematized humoral medicine for the next millennium and a half and is traditionally credited with popularizing “rheumatism” in this sense. Under this framework, gout, what we now call rheumatoid arthritis, osteoarthritis, and ordinary joint aches were not sharply separated diseases but variations on a single theme of fluxes and imbalances lodging in the joints.

It is worth being precise about credit here. Hippocrates and Galen described joint diseases vividly and durably, and named several syndromes by location — but they did not discover or define the specific modern entities. Their podagra is the historical thread leading to gout; their broad “rheumatism” is the tangle that later centuries would have to comb apart.

Back to Table of Contents

When “Rheumatism” Was One Disease

For most of recorded history, the various arthritides were not distinguished. Through the medieval and early-modern periods, chronic joint disease was generally lumped together as “gout,” “rheumatism,” or “arthritis,” with the humoral picture providing the explanation. A swollen, deformed hand and a sore, worn knee and an acutely inflamed big toe might all be filed under the same broad heading, because the underlying mechanisms — cartilage loss, autoimmunity, crystal deposition — were completely unknown.

The one partial exception was gout, which announced itself with such dramatic, sudden, often single-joint attacks (classically the great toe) that it was frequently recognized as something of its own even in antiquity. Even so, the deeper cause stayed hidden until the nineteenth century: it was the English physician Sir Alfred Baring Garrod who, in 1848, demonstrated an excess of uric acid in the blood of gout patients — the first chemical handle on any form of arthritis, and a finding that finally set gout apart on a firm mechanistic basis. (Garrod, as we will see, would also name rheumatoid arthritis a decade later.) The site’s companion page on Gout covers that uric-acid story in detail.

The decisive untangling of the chronic arthritides — separating the autoimmune from the degenerative — belongs almost entirely to the nineteenth century, and it began, fittingly, with a careful young observer in a Paris hospice.

Back to Table of Contents

Rheumatoid Arthritis: First Described (Landré-Beauvais, 1800)

The first clear clinical description of rheumatoid arthritis as a distinct illness is widely credited to the French physician Augustin Jacob Landré-Beauvais (1772–1840), in his 1800 doctoral dissertation in Paris. Working at the famed Salpêtrière hospice, Landré-Beauvais studied a group of mostly poor, long-resident women suffering from a chronic, deforming joint disease that did not fit the classic picture of gout. He called it goutte asthénique primitive — “primary asthenic gout” — using the only category available to him, but he carefully noted features that set it apart: a strong predominance in women, a chronic rather than acutely intermittent course, simultaneous involvement of many joints from the outset, and a decline in the patient’s general health.

Two points of historical honesty matter here. First, this is a case of first description, not naming: Landré-Beauvais filed the disease under the existing (and, to us, misleading) label of “gout” — the modern name would come more than half a century later. Second, his priority, while widely accepted, is not absolutely uncontested; medical historians sometimes point to earlier hints of similar conditions, and the broader debate about whether rheumatoid arthritis is an ancient or a relatively recent disease (the “1800 question”) draws directly on the fact that Landré-Beauvais’s account is the first one historians regard as unmistakable. What is solid is that his 1800 thesis is the earliest recognized, detailed clinical portrait of what we now call rheumatoid arthritis.

Back to Table of Contents

Rheumatoid Arthritis: Named (Garrod, 1859)

The disease got its modern name from the English physician Sir Alfred Baring Garrod (1819–1907). In his 1859 work The Nature and Treatment of Gout and Rheumatic Gout, Garrod proposed the term “rheumatoid arthritis” for the chronic deforming joint disease that earlier writers had variously called rheumatic gout, arthritis deformans, or asthenic gout. The coinage was deliberate and clarifying. Having already shown (in 1848) that gout involved excess uric acid — and finding no such uric-acid excess in these other patients — Garrod argued that this was a separate disease, neither true gout nor acute rheumatic fever, and the name “rheumatoid” (meaning “resembling rheumatism”) signaled exactly that: a condition that looks like rheumatism but is its own entity.

So the standard, well-sourced division of credit is: Landré-Beauvais (1800) first described it; Garrod (1859) named it. The term did not win acceptance overnight — competing labels lingered for decades, and the British Ministry of Health and later the American Rheumatism Association only formally settled on “rheumatoid arthritis” in the early-to-mid twentieth century — but Garrod’s 1859 coinage is the origin of the name in universal use today. Garrod is, with some justice, often called a father of modern rheumatology: he gave the field both the biochemical definition of gout and the name of its other great chronic disease.

Back to Table of Contents

Osteoarthritis Splits Off

Even after rheumatoid arthritis was named, it was not yet cleanly separated from the other great chronic joint disease — the common “wear-and-tear” degeneration of cartilage we now call osteoarthritis. For much of the nineteenth century the two were entangled under shared labels such as arthritis deformans, and the very word that would come to mean degenerative disease was, at first, applied to the wrong thing. The term “osteoarthritis” is generally credited to the English physician John Kent Spender of Bath, who used it in the 1880s — but, confusingly, Spender used “osteoarthritis” to denote what we would now call rheumatoid arthritis. (One of his books is even titled, to modern eyes paradoxically, The Early Symptoms and the Early Treatment of Osteo-Arthritis, Commonly Called Rheumatoid Arthritis.)

The clean modern split came as nineteenth- and early-twentieth-century clinicians and pathologists divided chronic arthritis into an “atrophic” type (inflammation and erosion of bone — the rheumatoid family) and a “hypertrophic” type (excess bony overgrowth around the joint — degenerative disease). Over time, “osteoarthritis” settled onto the hypertrophic, degenerative category and “rheumatoid arthritis” onto the inflammatory, autoimmune one — reversing Spender’s original usage and giving us the two terms in their present meanings. The arrival of X-rays after 1895 was decisive: radiographs let physicians actually see the difference — the marginal erosions of rheumatoid disease versus the joint-space narrowing and osteophytes of osteoarthritis — turning a verbal dispute into a visible distinction.

The bottom line is that the two diseases ordinary people most often mean by “arthritis” — degenerative osteoarthritis and autoimmune rheumatoid arthritis — were only firmly pried apart, and given their now-standard names, within roughly the past 150 years, despite both being visible in skeletons thousands of years old.

Back to Table of Contents

The Rheumatoid Factor and Cortisone

The twentieth century turned rheumatoid arthritis from a clinical pattern into a measurable, treatable disease. On the diagnostic side, the key discovery was the rheumatoid factor — an antibody found in the blood of many rheumatoid-arthritis patients. The Norwegian physician Erik Waaler first reported the underlying agglutination phenomenon in 1940 (building on an unusual result he had noticed in 1937), and the American physician Harry M. Rose, with colleagues, independently rediscovered and developed it into a practical diagnostic test in 1948. The resulting assay became known as the Waaler-Rose test (or Rose-Waaler test) and gave clinicians, for the first time, a blood marker for the disease — the ancestor of the rheumatoid-factor and later anti-CCP antibody tests still used today.

On the treatment side came one of the most dramatic episodes in twentieth-century medicine. At the Mayo Clinic, the rheumatologist Philip Showalter Hench, working with the biochemist Edward Kendall, gave an adrenal-cortex steroid then called “Compound E” — soon known as cortisone — to a severely disabled rheumatoid-arthritis patient (Mrs. G.) on 21 September 1948. The effect was astonishing: bed-bound, crippled patients were walking within days. Hench, Kendall, and Switzerland’s Tadeus Reichstein shared the 1950 Nobel Prize in Physiology or Medicine for the work on adrenal-cortex hormones. Cortisone was not the cure it first appeared to be — its side effects soon tempered the early euphoria — but it proved that inflammation in rheumatoid arthritis could be powerfully suppressed, opening the modern era of anti-inflammatory and, eventually, immune-targeted therapy.

These mid-century milestones — a blood test and a steroid — mark the point at which rheumatoid arthritis fully became a disease that could be both detected in the lab and altered by treatment, rather than merely described at the bedside.

Back to Table of Contents

Willow Bark to Aspirin: An Ancient Remedy

If naming the arthritides took millennia, treating their pain has an equally long and far more continuous history — one that runs from a tree to the most-used drug in the world. Extracts of willow bark (genus Salix) and the related meadowsweet were folk remedies for fever and aching joints in many ancient cultures; the bark’s bitter active principle would later be named salicin, from salix, the Latin for willow. A frequently repeated claim that Hippocrates specifically prescribed willow bark for joint pain is more legend than documented fact and should be treated with caution, but the broad antiquity of willow as a pain-and-fever remedy is well attested.

The modern scientific chain is firmly dated. In 1763, the English clergyman Reverend Edward Stone reported to the Royal Society that dried willow bark relieved fever and ague — the first published clinical account in the European medical record. In 1828 the German pharmacist Johann Buchner isolated salicin; in 1838 the Italian chemist Raffaele Piria converted it to salicylic acid. Salicylic acid and its salt sodium salicylate worked against the pain, fever, and inflammation of rheumatism — and were used in large doses for arthritis — but they savagely irritated the stomach.

The solution came at the Bayer company in Germany, where the chemist Felix Hoffmann prepared a stable, purer, better-tolerated form — acetylsalicylic acid — on 10 August 1897. Bayer marketed it from 1899 under the name Aspirin. (Bayer’s own histories credit Hoffmann; a long-standing scholarly dispute holds that his colleague Arthur Eichengrün directed the work, a credit question that remains genuinely contested.) Either way, aspirin became the first mass-produced anti-inflammatory and the foundation of the entire class of nonsteroidal anti-inflammatory drugs (NSAIDs) that, alongside the cortisone discovered fifty years later, still anchors the everyday treatment of arthritis pain. The willow remedy of antiquity and the molecular pharmacology of the twentieth century are, in this one unbroken thread, the same story.

Back to Table of Contents

Research Papers and References

The references below combine peer-reviewed historical and paleopathological literature with curated PubMed topic-search links covering the discovery and naming of the major arthritides, the rheumatoid factor, cortisone, and the willow-bark-to-aspirin story. Historical primary texts (the Hippocratic corpus, Galen, Landré-Beauvais’s 1800 dissertation, and Garrod’s 1859 treatise) are named in the article as historical sources. Each link opens at the National Library of Medicine in a new tab.

  1. Tsoucalas G, Sgantzos M. Primary Asthenic Gout by Augustin-Jacob Landré-Beauvais in 1800: Is this the first description of Rheumatoid Arthritis? Mediterranean Journal of Rheumatology. — PMC7045995
  2. Landré-Beauvais AJ. The first description of rheumatoid arthritis: unabridged text of the doctoral dissertation presented in 1800 (translated reprint). Joint Bone Spine. 2001. — PMID 11324929
  3. Storey GD. Alfred Baring Garrod (1819–1907). Rheumatology (Oxford). — PubMed: Alfred Baring Garrod and the history of rheumatoid arthritis
  4. Parish LC. An historical approach to the nomenclature of rheumatoid arthritis. Arthritis & Rheumatism. 1963;6(2):138–158. — PubMed: nomenclature of rheumatoid arthritis
  5. The discovery of the rheumatoid factor. I. Erik Waaler, 1940 (historical reprint and commentary). — PMID 9631762
  6. Waaler-Rose test — eponym and history of the rheumatoid-factor agglutination assay (Waaler 1940; Rose et al. 1948). — PubMed: Waaler-Rose test rheumatoid factor history
  7. Hench PS, Kendall EC, Slocumb CH, Polley HF. The effect of a hormone of the adrenal cortex (compound E) on rheumatoid arthritis (1949) — the cortisone trial and 1950 Nobel Prize. — PubMed: Hench Kendall cortisone in rheumatoid arthritis
  8. Entezami P, Fox DA, Clapham PJ, Chung KC. Historical perspective on the etiology of rheumatoid arthritis. Hand Clinics. 2011. — PMC3119866
  9. Dequeker J, Luyten FP. The history of osteoarthritis–osteoarthrosis. Annals of the Rheumatic Diseases. — PubMed: history of osteoarthritis and the term’s origin
  10. Aceves-Avila FJ, et al. The antiquity of rheumatoid arthritis: paleopathology and the “New World” hypothesis. — PubMed: antiquity of rheumatoid arthritis and paleopathology
  11. History of arthritis and bone rarefaction: evidence from paleopathology onwards. — PMID 10218229
  12. Nuki G, Simkin PA. A concise history of gout and hyperuricemia and their treatment (Hippocrates’ podagra to Garrod’s uric acid). Arthritis Research & Therapy. 2006. — PMC3226106
  13. Desborough MJR, Keeling DM. The aspirin story — from willow to wonder drug (Stone 1763; salicin; Hoffmann 1897). British Journal of Haematology. — PubMed: history of aspirin from willow bark to acetylsalicylic acid
  14. Stone E. An account of the success of the bark of the willow in the cure of agues (1763) — commentary reprint. Philosophical Transactions of the Royal Society. — PMC4360122

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents